NAFDAC: Issues DRAP Drug Recall Alert for Substandard Medicines

• NAFDAC has issued Public Alert No. 038/2026 regarding specific adulterated and substandard medicines.
• The Drug Regulatory Authority of Pakistan (DRAP) initiated the recall due to quality defects and contamination concerns.
• The recalled drugs include Nitras, Kadin 2, Acefyl, and Loratadine 24.
• The alert targets healthcare professionals, importers, distributors, retailers, and the general public in Nigeria.
• Stakeholders must immediately verify their inventory to prevent the distribution of these recalled products and ensure compliance with NAFDAC directives.

Lawyers advising pharmaceutical companies, importers, distributors, or healthcare providers in Nigeria must immediately verify if any of the listed drugs are in their supply chain or inventory to prevent the continued distribution of recalled products and to mitigate potential liability arising from the circulation of substandard medicines.

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a critical public alert, designated as No. 038/2026, concerning several pharmaceutical products identified as adulterated and substandard. This notification serves as a crucial warning to all stakeholders within Nigeria's healthcare and pharmaceutical supply chains. The agency's proactive measure aims to safeguard public health by preventing the distribution and use of potentially harmful medications.

The impetus for this alert originated from the Drug Regulatory Authority of Pakistan (DRAP), which initiated a recall of specific batches of these medicines. DRAP's action was prompted by serious quality deficiencies, including confirmed contamination issues and a general failure of the products to adhere to established quality standards. Such findings underscore the global interconnectedness of pharmaceutical regulation and the necessity for international cooperation in ensuring drug safety.

The particular drugs subject to this recall are Nitras, Kadin 2, Acefyl, and Loratadine 24. The identified quality defects and contamination concerns associated with these products pose significant health risks to consumers. NAFDAC's alert emphasizes the importance of vigilance across the entire distribution network to intercept these substandard items before they reach patients.

NAFDAC's role as Nigeria's primary regulatory body for food and drugs mandates it to protect public health by ensuring that all regulated products are safe, efficacious, and of the required quality. The issuance of Public Alert No. 038/2026 is a direct fulfillment of this mandate, demonstrating the agency's commitment to monitoring and responding to threats posed by substandard pharmaceutical products, regardless of their origin.

The collaboration with international bodies like DRAP highlights the comprehensive approach required to combat the circulation of illicit or compromised medicines. When a foreign regulatory authority identifies issues with products that may enter or are already present in the Nigerian market, NAFDAC acts swiftly to disseminate this information and enforce necessary measures. This cross-border regulatory intelligence is vital for maintaining the integrity of the national drug supply.

The reasons cited for DRAP's recall—quality defects, contamination concerns, and non-compliance with standards—are grave. Such issues can lead to ineffective treatment, adverse drug reactions, or even life-threatening conditions for patients. NAFDAC's alert is therefore a critical step in preventing potential harm and upholding the public's trust in the pharmaceutical products available within the country.

This NAFDAC DRAP drug recall alert carries significant implications for a wide array of stakeholders in Nigeria. Healthcare professionals, including doctors, pharmacists, and nurses, are urged to immediately cease dispensing or administering any identified batches of Nitras, Kadin 2, Acefyl, and Loratadine 24. Their prompt action is essential to prevent patient exposure to these substandard medicines and to uphold professional standards of care.

Importers, distributors, and retailers within the Nigerian pharmaceutical supply chain bear a primary responsibility to verify their inventory and supply lines. It is imperative that they conduct thorough checks to identify and quarantine any affected batches of these recalled drugs. Failure to comply with this directive not only risks public health but also exposes these entities to severe regulatory penalties and potential legal liabilities for distributing adulterated products.

Lawyers advising pharmaceutical companies, importers, distributors, or healthcare providers in Nigeria must immediately verify if any of the listed drugs are in their supply chain or inventory to prevent the continued distribution of recalled products and to mitigate potential liability arising from the circulation of substandard medicines. Ensuring strict compliance with NAFDAC directives is paramount for all entities involved in the drug supply chain to avoid legal repercussions and maintain regulatory standing.

Lawyers advising pharmaceutical companies, importers, distributors, or healthcare providers in Nigeria must immediately verify if any of the listed drugs are in their supply chain or inventory to prevent distribution of recalled products and mitigate potential liability for substandard medicines, ensuring compliance with NAFDAC directives.

Source: Original reporting via regulatory alert.